|04/09/14||The Medicines Company to Announce First Quarter 2014 Financial Results on Wednesday, April 23, 2014|
|Conference Call to Be Held at 8:30 a.m. Eastern Time
PARSIPPANY, NJ -- (Marketwired) -- 04/09/14 --
The Medicines Company (NASDAQ: MDCO) has scheduled its quarterly conference call for Wednesday, April 23 at 8:30 a.m. Eastern Time to discuss first quarter 2014 financial results, operational developments, and outlook for 2014.
The conference call will be available via phone and webcast. The dial-in information is listed below:
Domestic Dial In: + 1 877-359-9508
International Dial ... |
|04/03/14||FDA Accepts the Filing of The Medicines Company's US Biologic License Application for Fibrocaps Hemostatic Agent|
|PARSIPPANY, NJ -- (Marketwired) -- 04/03/14 --
The Medicines Company (NASDAQ: MDCO) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of a biologic license application (BLA) for the investigational hemostatic agent Fibrocaps, a dry powder formulation of fibrinogen and thrombin being developed to aid in hemostasis during surgery, where control of mild or moderate bleeding by conventional means is ineffective or impractical. The FDA action date (PDUFA date)... |
|03/31/14||Update on Angiomax® (Bivalirudin) Patent Litigation|
|PARSIPPANY, NJ -- (Marketwired) -- 03/31/14 -- The Medicines Company (NASDAQ: MDCO) -- On March 31, 2014, Judge Andrews in the U.S. District Court of Delaware issued his Trial Opinion in The Medicines Company v. Hospira, Inc. The case involves Hospira's Abbreviated New Drug Applications ("ANDAs") seeking approval to commercially manufacture, use or sell a generic version of The Medicines Company's Angiomax® bivalirudin drug product before the expiration of the patents covering this product.
|03/30/14||Analysis of EUROMAX and HORIZONS-AMI Trials of The Medicines Company's Angiomax® (Bivalirudin) Presented at ACC.14|
|New Pooled Analysis of 5,800 Patients Shows Bivalirudin Associated With Reductions in Cardiac Death, Major Bleeding, Transfusion and NACE in STEMI Patients Undergoing PCI; Results Consistent With Previous Results From HORIZONS-AMI and EUROMAX
WASHINGTON, DC -- (Marketwired) -- 03/30/14 -- The Medicines Company (NASDAQ: MDCO) today reported a presentation of a pooled analysis of 5,800 patients in the EUROMAX and HORIZONS-AMI trials, two international clinical trials comparing Angiomax® (bivaliru... |